These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1144 related articles for article (PubMed ID: 36747242)

  • 1. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
    Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
    Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
    Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
    Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 detection using
    Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
    J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
    Zhong YM; Yin K; Chen Y; Xie Z; Lv ZY; Yang JJ; Yang XN; Zhou Q; Wang BC; Zhong WZ; Gao LL; Zhou WB; Chen J; Tu HY; Liao RQ; Zhang DK; Zhang SL; Lu DX; Zheng HB; Zhang HH; Wu YL; Zhang XC
    Front Immunol; 2022; 13():951817. PubMed ID: 36263036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
    Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
    Front Immunol; 2020; 11():624547. PubMed ID: 33552089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
    Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
    Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective.
    Lavacchi D; Pellegrini E; Palmieri VE; Doni L; Mela MM; Di Maida F; Amedei A; Pillozzi S; Carini M; Antonuzzo L
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies.
    Matsumoto A; Nakashima C; Kimura S; Sueoka E; Aragane N
    BMC Cancer; 2021 May; 21(1):584. PubMed ID: 34022841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
    Singh N; Temin S; Baker S; Blanchard E; Brahmer JR; Celano P; Duma N; Ellis PM; Elkins IB; Haddad RY; Hesketh PJ; Jain D; Johnson DH; Leighl NB; Mamdani H; Masters G; Moffitt PR; Phillips T; Riely GJ; Robinson AG; Rosell R; Schiller JH; Schneider BJ; Spigel DR; Jaiyesimi IA
    J Clin Oncol; 2022 Oct; 40(28):3323-3343. PubMed ID: 35816668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.
    Hong L; Negrao MV; Dibaj SS; Chen R; Reuben A; Bohac JM; Liu X; Skoulidis F; Gay CM; Cascone T; Mitchell KG; Tran HT; Le X; Byers LA; Sepesi B; Altan M; Elamin YY; Fossella FV; Kurie JM; Lu C; Mott FE; Tsao AS; Rinsurongkawong W; Lewis J; Gibbons DL; Glisson BS; Blumenschein GR; Roarty EB; Futreal PA; Wistuba II; Roth JA; Swisher SG; Papadimitrakopoulou VA; Heymach JV; Lee JJ; Simon GR; Zhang J
    J Thorac Oncol; 2020 Sep; 15(9):1449-1459. PubMed ID: 32389639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of response factors for monotherapy with immune checkpoint inhibitors in non-small cell lung cancer patients with PD-L1 expression <50.
    Takahara Y; Abe R; Sumito N; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Nishiki K; Nojiri M; Kato R; Shinomiya S; Oikawa T
    Thorac Cancer; 2023 Sep; 14(27):2754-2760. PubMed ID: 37536667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study.
    Yip W; Ghoreifi A; Gerald T; Lee R; Howard J; Asghar A; Khanna A; Cai J; Aron M; Gill I; Thompson RH; Uzzo R; Margulis V; Singla N; Djaladat H
    Eur Urol Oncol; 2023 Dec; 6(6):604-610. PubMed ID: 37005212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
    Tajarernmuang P; Ofiara L; Beaudoin S; Wang H; Benedetti A; Gonzalez AV
    Chest; 2021 Aug; 160(2):743-753. PubMed ID: 33675792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma.
    An Z; Hsu MA; Gicobi JK; Xu T; Harrington SM; Zhang H; Pavelko KD; Hirdler JB; Lohse CM; Nabavizadeh R; Pessoa RR; Sharma V; Thompson RH; Leibovich BC; Dong H; Lucien F
    J Immunol; 2023 Jun; 210(12):2029-2037. PubMed ID: 37163328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.